Prognostic Significance of PD-L1 Expression on Circulating Myeloid-Derived Suppressor Cells in NSCLC Patients Treated with Anti-PD-1/PD-L1 Checkpoint Inhibitors
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252212269 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Roser Salvia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Functional Cytomics Lab, Germans Trias i Pujol Research Institute (IGTP), Campus Can Ruti, Crta. de Can Ruti, Camí de les Escoles, s/n, 08916 Badalon…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Myeloid-Derived Suppressor Cells, B7-H1 Antigen, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thermo Fisher Scientific (USA), La Caixa, CERCA.
Abstract (Originalsprache)
Even though anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) have improved survival, a high percentage of patients still do not respond to ICIs. Myeloid-derived suppressor cells (MDSCs) are circulating cells that express PD-L1 and can infiltrate and proliferate in the tumor microenvironment, inducing immunosuppression. By evaluating changes in PD-L1 expression of live peripheral blood MDSCs, we are able to define a new PD-L1 index, useful in predicting ICI escape in NSCLC patients before initiating anti-PD-1/PD-L1 immunotherapy. In this study, a cohort of 37 NSCLC patients was prospectively analyzed, obtaining independent PD-L1 indexes. In patients with a PD-L1 index > 5.88, progressive disease occurred in 58.33% of patients [median progression-free survival (PFS) = 5.73 months; 95%CI = 2.67–20.53], showing significant differences when compared with patients with a PD-L1 index ≤ 5.88, in whom 7.69% progressed and median PFS was not reached (NR); p-value = 0.0042. Overall survival (OS) was significantly worse in patients with a high vs. low PD-L1 index (41.67% vs. 76.92%; median OS = 18.03 months, 95%CI = 6.77–25.23 vs. NR, 95%CI = 1.87-NR; p-value = 0.035). The PD-L1 index can be applied to stratify NSCLC patients according to their probability of response to ICIs at baseline. In addition to quantifying tumoral expression, this index could be used to compare nonresponse to treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Functional Cytomics Lab, Germans Trias i Pujol Research Institute (IGTP), Campus Can Ruti, Crta. de Can Ruti, Camí de les Escoles, s/n, 08916 Badalona, Spain.
- Department of Cellular Biology, Physiology and Immunology, Autonomous University of Barcelona (UAB), 08193 Cerdanyola del Vallès, Spain.
- Medical Oncology Department, Catalan Institute of Oncology Badalona (ICO), Germans Trias i Pujol University Hospital (HUGTiP), 08916 Badalona, Spain.
- Applied Research Group in Oncology, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain.
- Department of Medicine, Autonomous University of Barcelona (UAB), 08193 Cerdanyola del Vallès, Spain.
- Thermo Fisher Scientific, Fort Collins, CO 80524, USA.
ORCID-Profile: Roser Salvia, Teresa Morán, Rafael Rosell, Jordi Petriz
Förderung
- Thermo Fisher Scientific (USA)
- La Caixa
- CERCA
- Agency for Management of University and Research Grants (AGAUR, Generalitat de Catalunya)
- Catalan Research Group (SGR)
- Sartorius Stedim North America, Inc.
Zitieren
APA
Salvia, R., Rico, L. G., Morán, T., Bradford, J. A., Ward, M. D., Drozdowskyj, A., Climent-Martí, J., Martínez-Cáceres, E. M., Rosell, R., & Petriz, J. (2024). Prognostic Significance of PD-L1 Expression on Circulating Myeloid-Derived Suppressor Cells in NSCLC Patients Treated with Anti-PD-1/PD-L1 Checkpoint Inhibitors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252212269
Vancouver
Salvia R, Rico LG, Morán T, Bradford JA, Ward MD, Drozdowskyj A, et al. Prognostic Significance of PD-L1 Expression on Circulating Myeloid-Derived Suppressor Cells in NSCLC Patients Treated with Anti-PD-1/PD-L1 Checkpoint Inhibitors. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252212269
BibTeX
@article{Salvia2024,
author = {Salvia, Roser and Rico, Laura G and Morán, Teresa and Bradford, Jolene A and Ward, Michael D and Drozdowskyj, Ana and Climent-Martí, Joan and Martínez-Cáceres, Eva M and Rosell, Rafael and Petriz, Jordi},
title = {Prognostic Significance of PD-L1 Expression on Circulating Myeloid-Derived Suppressor Cells in NSCLC Patients Treated with Anti-PD-1/PD-L1 Checkpoint Inhibitors},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252212269}
}
EUVIMED